The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Bod Science's quick ratio for the quarter that ended in Jun. 2025 was 0.28.
Bod Science has a quick ratio of 0.28. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Bod Science's Quick Ratio or its related term are showing as below:
ASX:BOD'
s Quick Ratio Range Over the Past 10 Years
Min: 0.21 Med: 2.12 Max: 5.66
Current: 0.28
During the past 9 years, Bod Science's highest Quick Ratio was 5.66. The lowest was 0.21. And the median was 2.12.
ASX:BOD's Quick Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.45
vs ASX:BOD: 0.28
Bod Science (ASX:BOD) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Bod Science Quick Ratio Related Terms
Bod Science Quick Ratio Historical Data
* Premium members only.
The historical data trend for Bod Science's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bod Science's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bod Science Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bod Science's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Bod Science's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Bod Science's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bod Science (ASX:BOD) has a Quick Ratio of 0.28 as of Jun. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Bod Science and its competitors. This is 87% below median its historical median of 2.12. Over the past decade, Bod Science's Quick Ratio has ranged from 0.21 to 5.66.
Is Bod Science's Quick Ratio too high?
Bod Science's current Quick Ratio of 0.28 is 87% below median its 10-year median of 2.12. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 5.66. The Drug Manufacturers industry median Quick Ratio is 1.45. Bod Science's value of 0.28 is 80.7% below this industry median. Overall, Bod Science has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bod Science's Quick Ratio compare to ZTS?
Bod Science's Quick Ratio of 0.28 can be compared against companies in the Drug Manufacturers industry. The industry median Quick Ratio is 1.45. Bod Science's value of 0.28 is 80.7% below this benchmark. Historically, Bod Science's own Quick Ratio has ranged from 0.21 to 5.66 over the past decade. While the company's 10-year median is 2.12 vs. the industry median of 1.45, Bod Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bod Science's current Quick Ratio of 0.28 is 80.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Bod Science and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bod Science's current Quick Ratio is 0.28, which is 87% below median its own 10-year median of 2.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bod Science stock overvalued right now?
Bod Science (ASX:BOD) has a current Quick Ratio of 0.28. The stock's GF Value™ is A$0.04, compared to a current price of A$0.02 — trading 40% below its estimated fair value. The current Quick Ratio is 0.28, which is 87% below median its 10-year median of 2.12 and 80.7% below the Drug Manufacturers industry median of 1.45. Bod Science's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Bod Science (ASX:BOD), the current Quick Ratio is 0.28 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bod Science (ASX:BOD) Overvalued in 2026?
Based on GuruFocus' analysis, Bod Science stock appears to be undervalued.
The current stock price of A$0.02 is trading 40% below its estimated GF Value™ of A$0.04.
Key valuation signals for ASX:BOD:
Quick Ratio: 0.28 (87% below median its 10-year median of 2.12)
GF Value™: A$0.04 vs. price of A$0.02 (40% below fair value)
Industry Position: 80.7% below the Drug Manufacturers median
No single metric tells the full story. See the ASX:BOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bod Science Ltd is a healthcare company combining the power of nature and science to deliver cannabis-derived health and skincare products, designed to improve lives and transform the medicinal cannabis, CBD, and hemp market. The firm is focused on cannabis drug development and products. The company is focused on progressing Research and Development and a defined clinical trial pathway to commercialize and deliver premium, scientifically trusted products for the consumer and medical markets. It earned it profits and sales revenue from Australia even though have segment in UK, Europe and USA.
12GF Score
Get the complete analysis for ASX:BOD
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BOD has been successfully added to your 
